362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Authors :: Carlo Toniatti
M. Stroh
W.R. Schelman
Christopher L. Carpenter
L. Sun
Robert M. Wenham
J. De-Bono
G. Wilding
Shahneen Sandhu
Richard D. Baird
Source :: European Journal of Cancer Supplements. 8:114-115
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Antitumor activity
Cancer Research
Oncology
business.industry
Poly ADP ribose polymerase
PARP inhibitor
Medicine
First in human
business
Advanced cancer
Molecular biology

Full Text Access

Tools